February 22, 2017
(Nature) – Berkeley filed for a patent earlier, but the USPTO granted the Broad’s patents first — and this week upheld them. There are high stakes involved in the ruling. The holder of key patents could make millions of dollars from CRISPR–Cas9’s applications in industry: already, the technique has speeded up genetic research, and scientists are using it to develop disease-resistant livestock and treatments for human diseases. But the fight for patent rights to CRISPR technology is by no means over. Here are four reasons why.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.